We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+45.54%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
-$48M
Cap. Flow
-$51.8M
Cap. Flow %
-39.17%
Top 10 Hldgs %
58.69%
Holding
110
New
19
Increased
5
Reduced
6
Closed
42

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$9.06M
2
GRI
GRI Bio
GRI
+$8.89M
3
IMGN
Immunogen Inc
IMGN
+$5.73M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.5M
5
JSPR icon
Jasper Therapeutics
JSPR
+$4.26M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$8.15M
2
ACLX
Arcellx
ACLX
+$4.62M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$4.58M
4
GKOS icon
Glaukos
GKOS
+$4.56M
5
PEN icon
Penumbra
PEN
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
2 Financials 1.18%
3 Technology 1.18%
4 Communication Services 0.44%
5 Materials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
26
Karyopharm Therapeutics
KPTI
$46.2M
$1.32M 1%
49,333
+15,614
+46% +$672K
PEPL
27
DELISTED
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
$1.04M 0.79%
100,000
– –
CYCU
28
Cycurion Inc
CYCU
$9.46M
$1.04M 0.79%
3,360
– –
KOD icon
29
Kodiak Sciences
KOD
$2.66B
$1.03M 0.78%
+150,000
New +$917K
FATBW
30
DELISTED
FAT Brands Inc. Warrant
FATBW
$776K 0.59%
227,000
– –
IMVT icon
31
Immunovant
IMVT
$8.14B
$666K 0.5%
+35,100
New +$655K
MRSN
32
CALL
DELISTED
Mersana Therapeutics
MRSN
$658K 0.5%
8,004
-22,000
-73% -$3.22M
DDI
33
DoubleDown Interactive
DDI
$594M
$583K 0.44%
60,876
– –
PSQH icon
34
PSQ Holdings
PSQH
$15.7M
$514K 0.39%
3,333
– –
OHAA
35
DELISTED
OPY Acquisition Corp. I Class A Common Stock
OHAA
$512K 0.39%
50,000
– –
POL.WS
36
DELISTED
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
$396K 0.3%
6,103,824
– –
WLDSW icon
37
Wearable Devices Ltd Warrant
WLDSW
$282K 0.21%
1,961
– –
POL
38
DELISTED
Polished.com Inc.
POL
$265K 0.2%
11,521
– –
MRAI
39
DELISTED
Marpai, Inc. Class A Common Stock
MRAI
$202K 0.15%
+117,848
New +$339K
DRCTW
40
DELISTED
Direct Digital Holdings, Inc. Warrant
DRCTW
$108K 0.08%
180,000
– –
NXGLW icon
41
NexGel Inc Warrant
NXGLW
$97.2K 0.07%
225,000
– –
KYNB
42
CALL
Kyntra Bio
KYNB
$28.3M
$94.5K 0.07%
+1,400
New +$579K
MBTCR
43
DELISTED
Nocturne Acquisition Corporation Right
MBTCR
$62.5K 0.05%
+500,000
New +$61.4K
CINGW icon
44
Cingulate Inc Warrants
CINGW
$39.6K
$56.7K 0.04%
270,000
– –
NEXRW
45
Nexera Technologies Ltd Warrant
NEXRW
$41.4K
$55.7K 0.04%
480,770
-500,000
-51% -$59.1K
KYNB
46
PUT
Kyntra Bio
KYNB
$28.3M
$45.9K 0.03%
+680
New +$281K
ONFOW icon
47
Onfolio Holdings Warrant
ONFOW
$35.7K
$40K 0.03%
200,000
– –
BRSHW
48
DELISTED
Bruush Oral Care Inc. Warrant
BRSHW
$28.8K 0.02%
360,579
– –
NLSPW
49
DELISTED
NLS Pharmaceutics Warrant
NLSPW
$21.4K 0.02%
200,000
– –
BNCWW
50
CEA Industries Inc Warrant
BNCWW
$13.2K 0.01%
250,000
– –
1
2
3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
GC
Gruss & Co West Palm Beach, Florida $42.8M AUM 49.41% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return

Altium Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Altium Capital Management held 110 positions worth $132M, down 27% from $180M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Altium Capital Management withdrew a net $51.8M in Q2 2023, closing 42 positions and reducing 6 holdings. Its most notable exit was BELLUS Health Inc., an estimated $8.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Financials and Technology.

Against the trend, Altium Capital Management opened a new position in Xenon Pharmaceuticals worth $8.78M.

  • Altium Capital Management's largest Q2 2023 buy was Xenon Pharmaceuticals: 228,000 shares worth $8.78M.
  • Altium Capital Management added most to Harmony Biosciences in Q2 2023, an estimated $4.14M increase.
  • Altium Capital Management's biggest Q2 2023 reduction was ADMA Biologics, cutting an estimated $1.82M.
  • Altium Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $8.15M.
  • Altium Capital Management's ten largest holdings make up 59% of its $132M portfolio in Q2 2023.
  • Altium Capital Management opened 19 new positions and closed 42 in Q2 2023.
  • Altium Capital Management's portfolio value fell 27% quarter-over-quarter to $132M.

Based on Altium Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.